Correction - GSK

LONDON - Last week's edition of Campaign carried a story that was headlined: "GSK calls £300m media review."

Lucozade…a GSK brand
Lucozade…a GSK brand

We now accept that the story, which suggested that GlaxoSmithKline has called a review of its international media planning and buying arrangements, was incorrect.

GSK has no plans to review either globally or in any of its local markets now or in the near future, but is using Accenture and the US consultancy Medialink to conduct a standard audit of its media buying arrangements.

MediaCom continues to handle the GSK business in the majority of key markets across the world, including the US and UK, while Starcom MediaVest Group continues to handle the business in Central and Eastern Europe.

We apologise for any confusion caused by the story.

Become a member of Campaign

Get the very latest news and insight from Campaign with unrestricted access to, plus get exclusive discounts to Campaign events.

Become a member

What is Campaign AI?

Our new premium service offering bespoke monitoring reports for your company.

Find out more

Looking for a new job?

Get the latest creative jobs in advertising, media, marketing and digital delivered directly to your inbox each day.

Create an alert now

Partner content